Gary Jacob
Directeur Général chez OKYO PHARMA LIMITED
Fortune : 69 134 $ au 31/05/2024
Postes actifs de Gary Jacob
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACTAVIA LIFE SCIENCES, INC. | Directeur/Membre du Conseil | 23/12/2020 | - |
| Independent Dir/Board Member | 23/12/2020 | - | |
| OKYO PHARMA LIMITED | Directeur/Membre du Conseil | 07/01/2021 | - |
| Directeur Général | 07/01/2021 | - |
Historique de carrière de Gary Jacob
Anciens postes connus de Gary Jacob
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| HEPION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 15/05/2013 | 19/03/2014 |
| Directeur Général | 15/05/2013 | 19/03/2014 | |
| Président | 19/03/2014 | 20/02/2024 | |
| Independent Dir/Board Member | 19/03/2014 | 20/02/2024 | |
| President | 15/05/2013 | 19/03/2014 | |
| VIRPAX PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 28/04/2020 | 25/07/2022 |
| Independent Dir/Board Member | 28/04/2020 | 25/07/2022 | |
| IMMURON LIMITED | Directeur/Membre du Conseil | 17/04/2019 | 25/03/2020 |
| Directeur Général | 16/11/2018 | 25/03/2020 | |
| SYNERGY PHARMACEUTICALS INC | Directeur/Membre du Conseil | 29/03/2011 | 05/05/2014 |
| Directeur Général | 01/07/2008 | 19/12/2017 | |
| Président | 05/05/2014 | 01/01/2018 | |
| Fondateur | - | 01/01/2018 | |
| Investor Relations Contact | 29/03/2011 | 06/05/2014 | |
| Public Communications Contact | 24/08/2011 | 06/05/2014 | |
| President | 01/07/2008 | 19/12/2017 | |
| Synergy Pharmaceuticals, Inc. /Old/ | Directeur Général | 01/07/2008 | 01/10/2017 |
| Président | 01/09/2013 | 01/10/2017 | |
| Fondateur | 01/07/2008 | 01/10/2017 | |
| President | 01/07/2008 | 01/10/2017 | |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/05/2003 | 22/01/2013 |
| Directeur Général | 01/05/2003 | 22/01/2013 | |
| Directeur Technique/Scientifique/R&D | 01/05/2003 | 22/01/2013 | |
| Public Communications Contact | 01/05/2003 | 22/01/2013 | |
| President | 01/01/2004 | 22/01/2013 | |
| Pawfect Foods, Inc. | Directeur/Membre du Conseil | 11/08/2008 | 11/08/2008 |
| President | - | 11/08/2008 | |
| ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - | |
| ░░░░ ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Gary Jacob
| University of Wisconsin | Doctorate Degree |
| University of Missouri-St. Louis | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 14 |
| Royaume-Uni | 3 |
| Australie | 2 |
Opérationnelle
| Director/Board Member | 9 |
| Chief Executive Officer | 6 |
| President | 5 |
Sectorielle
| Health Technology | 10 |
| Consumer Services | 4 |
| Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| OKYO PHARMA LIMITED | Health Technology |
| HEPION PHARMACEUTICALS, INC. | Health Technology |
| CARDIFF ONCOLOGY, INC. | Health Technology |
| IMMURON LIMITED | Health Technology |
| ACTAVIA LIFE SCIENCES, INC. | Health Technology |
| VIRPAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Health Technology |
| Pawfect Foods, Inc. | Retail Trade |
| Synergy Pharmaceuticals, Inc. /Old/ | Health Technology |
| G.D. Searle LLC | |
| Synergy DE | |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Gary Jacob
- Expérience
